Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.

about

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.

Item

http://www.wikidata.org/entity/Q50512926

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Phase II study of radium-223 d ...... ion-resistant prostate cancer.

@en

Phase II study of radium-223 d ...... ion-resistant prostate cancer.

@nl

type

Item

label

Phase II study of radium-223 d ...... ion-resistant prostate cancer.

@en

Phase II study of radium-223 d ...... ion-resistant prostate cancer.

@nl

prefLabel

Phase II study of radium-223 d ...... ion-resistant prostate cancer.

@en

Phase II study of radium-223 d ...... ion-resistant prostate cancer.

@nl

P1476

Phase II study of radium-223 d ...... ion-resistant prostate cancer.

@en

P2093

Akira Yokomizo

http://www.w3.org/2001/XMLSchema#string

Atsushi Mizokami

http://www.w3.org/2001/XMLSchema#string

Hiroaki Kikukawa

http://www.w3.org/2001/XMLSchema#string

Hiroji Uemura

http://www.w3.org/2001/XMLSchema#string

Hirokazu Tsutsui

http://www.w3.org/2001/XMLSchema#string

Hirotsugu Uemura

http://www.w3.org/2001/XMLSchema#string

Iku Yamaguchi

http://www.w3.org/2001/XMLSchema#string

Junji Yonese

http://www.w3.org/2001/XMLSchema#string

Makoto Hosono

http://www.w3.org/2001/XMLSchema#string

Naoya Masumori

http://www.w3.org/2001/XMLSchema#string

P2860

Alpha emitter radium-223 and survival in metastatic prostate cancer

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 A

Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial.

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

Practical aspects of weekly docetaxel administration schedules.

Cancer to bone: a fatal attraction.

Metastasis: the seed and soil theory gains identity.

P2888

s10147-017-1176-0

P304

173-180

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10147-017-1176-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Go Kimura

P577

2017-08-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28770408

http://www.w3.org/2001/XMLSchema#string

P932

5809574

http://www.w3.org/2001/XMLSchema#string